ArticleFrontiers in microbiology2025
The mechanism of short-chain fatty acid in hypertriglyceridemic pancreatitis.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of the gut microbiota in hypertriglyceridemic acute pancreatitis: potential mechanisms and therapeutic implications.Therapeutic advances in gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The incidence of hypertriglyceridemia pancreatitis (HTGP) has been rising annually with a poor prognosis, and its pathogenesis is complex. In recent years, the role of gut microbiota and short-chain fatty acids (SCFAs) has gradually attracted attention in HTGP. Therefore, the aim of this study was to investigate the characteristic alterations in gut microbiota and SCFAs and their potential clinical significance and molecular mechanisms in HTGP. Materials and methods: This study collected feces and serum samples from 18 HTGP patients and 18 healthy volunteers. We compared baseline clinical characteristics, gut microbiota diversity (via 16S rRNA sequencing), and serum SCFA concentrations (using mass spectrometry and other techniques) between the two groups to identify characteristic alterations. Correlation analyses explored associations between microbiota, metabolites, and clinical parameters. Further animal models validated the Results: HTGP patients exhibited higher body mass index (BMI), triglyceride (TG) levels, metabolic complication incidence and disease severity scores. In addition, the gut microbiota showed significantly reduced richness and diversity in HTGP. Serum metabolomics analysis revealed significantly higher concentrations of isovaleric acid, decanoic acid and octanoic acid in HTGP patients, demonstrating good diagnostic value. Correlation analysis indicated that differential gut microbiota and metabolites were closely associated with clinical parameters. Animal experiments confirmed that butyrate can alleviate HTGP disease severity by inhibiting NF- κ B/NLRP3 pathway activation. Discussion: In summary, this study identified differential gut microbiota and SCFAs in HTGP patients compared to healthy volunteers, and confirmed that butyrate exerts a protective effect through NF-κB/NLRP3 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.